PLAINSBORO, N.J. — Novo Nordisk has launched Xultophy 100/3.6, a combination therapy insulin pen, at pharmacies nationwide.

Xultophy 100/3.6 combines the long-acting basal insulin Tresiba (insulin degludec U-100) with the No. 1-prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza (liraglutide 3.6 mg/ml) in a once-daily injection, Novo Nordisk said.

The prefilled pen is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes that’s inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).

Novo Nordisk noted that in clinical studies Xultophy 100/3.6 lowered A1C and blood sugar for 24 hours, including before and after meals. The medication can be taken any time of day with or without food, the company said.

“Continuing research and development to find safe and effective medications for people living with diabetes is important, particularly for those who require additional A1C-lowering options,” stated Dr. Steve Edelman, founder and director of Taking Control of Your Diabetes, a nonprofit organization focused on helping people with diabetes better manage their condition. “Now that Xultophy 100/3.6 is available, patients with type 2 diabetes who are uncontrolled on basal insulin have a new combination that can help achieve their individualized treatment goals.”

Novo Nordisk added that it’s working to secure access for Xultophy 100/3.6 on health plans nationwide. Eligible patients with commercial insurance can use the Xultophy 100/3.6 Savings Card to reduce co-payments to as low as $1 per day or $30 per month, as well as receive a free box of Novo Nordisk needles, the company said.